Overview


According to FutureWise analysis the market for alcoholic liver diseases treatment in 2023 is US$ 2.08 billion, and is expected to reach US$ Over 3 billion by 2031 at a CAGR of 6%.

Alcoholic liver disease (ALD) is referred to as the excess consumption of alcohol, which is associated with alcoholic liver diseases. Years of alcohol addiction can cause the liver to become inflamed and swollen. ALD is a major healthcare problem, a personal and social burden, and a significant reason for economic loss worldwide. The ALD spectrum includes alcoholic fatty liver, cirrhosis, alcoholic hepatitis, and the development of hepatocellular carcinoma. The diagnosis of alcoholic liver disease is based on clinical characteristics, including evidence of liver disease, a history of significant alcohol intake, and laboratory findings.

Addressing the underlying alcohol addiction is the paramount step in managing ALD. Abstinence is the hallmark of treatment for ALD, and nutritional therapy is the first line of treatment. The role of steroids in patients with mild to severe alcoholic hepatitis is gaining acceptance, with the condition that patients be evaluated for the effectiveness of therapy at one week. Pentoxifylline is especially effective in ALD patients with renal dysfunction. Biological therapies such as specific anti-TNFs have been disappointing and should probably not be used outside the clinical trial setting. Transplantation delivers positive results in patients with advanced ALD who have stopped alcohol consumption, with both long-term graft and patient survival showing exceptional outcomes.

FutureWise Market Research has published a report that provides an insightful analysis alcoholic liver diseases treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, alcoholic liver diseases treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Johnson And Johnson Betaine, Inc.
  • Sanofi
  • Upsher-Smith Laboratories, LLC
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Bayer AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Alcoholic Liver Diseases Treatment Market:

  • In January 2023- Takeda and Arrowhead Pharmaceuticals Inc. announced topline results from the Phase 2 SEQUOIA clinical study of investigational Fazirsiran for the treatment of a liver condition associated with alpha-1 antitrypsin deficiency (AATD-LD).
  • In March 2022- Pfizer Inc. announced that it acquired Arena Pharmaceuticals, a company that develops new potential treatments for immuno- inflammatory diseases.

The growing evidence supporting the effectiveness of natural compounds in inhibiting the progression of Alcoholic Liver Disease (ALD) is significantly boosting market growth during the forecast period. Natural compounds such as silymarin (derived from milk thistle), curcumin (found in turmeric), and antioxidants from green tea have shown promising results in preclinical and clinical studies, exhibiting their potential to attenuate liver inflammation, oxidative stress, and fibrosis associated with ALD. As consumers increasingly seek safer and complementary treatment options, the demand for natural compounds as adjunctive therapies for ALD is expected to rise, presenting pharmaceutical companies with opportunities to develop and market novel natural-based ALD treatments. Moreover, the emerging trend in treating alcoholic liver disease is the adoption of precision medicine approaches. Precision medicine involves personalizing treatments to individual patients based on their specific genetic, environmental, and sedentary lifestyles. By analyzing a patient's unique profile, healthcare providers have the capacity to identify the most suitable treatment options for better outcomes and reduced side effects. This approach holds promise in ALD management, as it allows for a more personalized and targeted treatment strategy, potentially leading to improved patient responses and overall disease control. As precision medicine technologies continue to advance, their integration into ALD treatment protocols is expected to become more widespread, transforming the landscape of ALD management during the forecast period. Furthermore, the complexity of Alcoholic Liver Disease (ALD) significantly hinders the growth of targeted therapies, contributing to the restraint in the market's growth. The complex nature of ALD, which involves various pathological processes such as inflammation, fibrosis, and cirrhosis, makes it challenging to identify a single treatment that may effectively address all aspects of the disease.

By Indication

  • Alcoholic Fatty Liver Disease
  • Alcoholic Liver Hepatitis
  • Liver Fibrosis
  • Liver Cirrhosis

By Treatment

  • Pentoxifylline
  • Glucocorticosteroids
    • Prednisone
    • Triamcinolone
    • Prednisolone
  • Betaine
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the growing number of liver disease patients caused by excessive alcohol consumption, unhealthy diet, and sedentary lifestyle. The government's renewed focus on providing the necessary treatments to patients at an affordable rate is also expanding the market for liver disease treatment. Significant market players in the region contribute to its growing dominance in the liver disease treatment market, further driving the growth of the target market during the forecast period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Alcoholic Liver Diseases Treatment Market By Indication, By Treatment, By Distribution Channel and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Alcoholic Liver Diseases Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Alcoholic Liver Diseases Treatment Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Alcoholic Liver Diseases Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Alcoholic Liver Diseases Treatment Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Alcoholic Fatty Liver Disease
        2. Alcoholic Liver Hepatitis
        3. Liver Fibrosis
        4. Liver Cirrhosis

  • 8.   Alcoholic Liver Diseases Treatment Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pentoxifylline
        2. Glucocorticosteroids
         2.1. Prednisone
         2.2. Triamcinolone
         2.3. Prednisolone
        3. Betaine
        4. Others

  • 9.   Alcoholic Liver Diseases Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Drug Stores
        4. Online Pharmacies
        5. Others

  • 10.   North America Alcoholic Liver Diseases Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Alcoholic Liver Diseases Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Alcoholic Liver Diseases Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Alcoholic Liver Diseases Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Johnson and Johnson Betaine, Inc.
                  1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sanofi
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Upsher-Smith Laboratories, LLC
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. F. Hoffmann-La Roche AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GlaxoSmithKline plc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Bayer AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by Upsher-Smith Laboratories, LLCinistrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

FAQ


Yes, there are ongoing research studies focused on finding new treatment options, including medications that target liver inflammation and fibrosis. These are in various stages of clinical trials.

Market share can vary based on geographic regions, treatment types, and the presence of leading pharmaceutical companies and healthcare providers. It requires specific data analysis to provide an accurate figure, which might be obtained from up-to-date market research reports.

The forecast for the market will involve projecting its growth and trends, which is dependent on factors like the prevalence of alcoholic liver diseases, advances in treatments, and changes in healthcare policies. Detailed market forecast reports by our research analysts could offer a predictive outlook.

Current "Alcoholic Liver Diseases Treatment Market Trends" include advancements in personalized medicine, improvements in diagnostic technologies, increased investment in research, and more integrated approaches to treatment involving both physical and psychological support.

The Alcoholic Liver Diseases Treatment Market faces challenges such as the high cost of treatments, the need for more effective therapy options, and the stigma associated with alcohol-related diseases that can limit patients' readiness to seek treatment. Additionally, stringent regulatory environments can often hinder the rapid development and approval of new treatments.

Related Market

North America Liver Disease Treatment Market

Read More

Liver Function Tests Market

Read More

Autoimmune Hepatitis Treatment Market

Read More

Alcoholic Hepatitis Therapeutics Market

Read More

Liver Cirrhosis Treatment Market

Read More
Partner

Our Clients